CClinicalTrials.gg
Not yet recruitingNCT07089225COSMIC- ReleafUpdated Sep 24, 2025

A Study in Patients Reporting Cannabis Use Followed With an Application-Based Cannabis Journal

An observational study in Cancer, sponsored by Scot Remick. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by Scot Remick · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
18 Years and older
Sex
All
01

Study summary

This study is being done because there is a significant lack of data on the use of cannabis amongst cancer patients. The investigators believe that the collection of this data will help researchers and clinicians better understand the needs and the impact of cannabis use in this specific patient population.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's planned enrollment of 45 is below the median of 204 across 1,683 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

This is the only study on the registry with Scot Remick as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Oncology patients, receiving active therapy or in follow up following active therapy, and treated within the MaineHealth Cancer Care Network (MHCCN).

Eligibility criteria

Inclusion Criteria:

  • Patients must be 18 years of age or older and able to give verbal informed consent to participate.
  • Patients must be able to speak, read and understand English.
  • Patients must report use of cannabis at time of study participation.
  • Patients must have access to internet and ability to download Releaf™ App (MoreBetter, Ltd.) to a smartphone or tablet and must use Releaf™ App (MoreBetter, Ltd.) for cannabis journaling.
  • Patients must be able to send and receive text messages, and be able to interact with web-pages on smartphone or tablet.
  • There are 2 scenarios that patients are eligible for participation, and are listed below:

    1. Patients must have a cancer diagnosis for which they are receiving active therapy defined as follows:

      • Surgery - must be within a 30-day pre- and/or post-operative (peri-operative) window if single modality of care. Patients must be 18 years of age or older and able to give verbal informed consent to participate.
      • Radiation - must be within a 30-day pre- (simulation planning phase) and/or post-radiation window if single modality of care.
      • Any anticancer systemic therapy including hormonal, biologic, targeted, and/or cytotoxic chemotherapy. Understandably, numerous patients recruited under surgery and/or radiation will receive systemic therapy as part of combined modality therapy, which is permissible. Regardless, all details regarding cancer diagnosis, stage, and treatment will be collected from the EMR, which will be detailed in the informed consent document.
    2. Any patient in follow-up by their primary oncology care provider and/or AYA and cardio-oncology survivorship clinic(s).
  • All patients must be treated within the MHCCN thus ensuring access to clinical data in our system-wide EMR (Epic).
  • Patients must obtain their cannabis either from a medical-use store, adult-use (recreational) store or both. Patients must obtain cannabis ONLY from medical/recreational stores. Illicit (or homegrown) sources are strictly prohibited.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Cannabis Use

    In patients who report using cannabis, investigators will measure frequency and dose of cannabis and cannabinoid use, purpose of use (i.e., seeking recreational vs. medicinal effects), type (e.g., flower, concentrate, edibles), route of administration (e.g., smoking, vaping, ingestion, tincture, oil), psychoactive and non-psychoactive content (THC vs. CBD/CBG/CBN content in product), and products sources (from medical dispensaries and/or regulated adult-use stores).

    Time frame: Enrollment + 6 months

Secondary outcomes

  1. Patient Reported Symptoms

    Investigators will measure patient-reported helpful and adverse effects of cannabis and cannabinoid use among cancer patients.

    Time frame: Enrollment + 6 months

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07089225
Lead sponsor
Scot Remick
Collaborators
National Cancer Institute (NCI)
Responsible party
Scot Remick (Oncology Research and Education Principal, MaineHealth) — Sponsor-investigator
First posted
Jul 28, 2025
Start date
Sep 30, 2025 (estimated)
Primary completion
Aug 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 24, 2025

Study contacts

Clinical Research Coodinator
Contact
ntro@mainehealth.org
207-550-1265
Research Program Manager
Contact
ntro@mainehealth.org
Scot Remick, MD
principal investigator · MaineHealth

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion